Relapsed/Refractory Chronic Lymphocytic Leukemia

Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell

Prevalence

20.0 / 100K

Incidence

4.7 / 100K/yr

8 drugs in development·5 companies·1 clinical trial

Drug Pipeline by Phase

Compare drugs

alxn2075 vs epcoritamabalxn2075 vs Sonrotoclaxalxn2075 vs Pirtobrutinib

Frequently asked questions

How many drugs are in development for Relapsed/Refractory Chronic Lymphocytic Leukemia?

BioSniper tracks 8 drugs in development for Relapsed/Refractory Chronic Lymphocytic Leukemia across 5 companies.

How many clinical trials target Relapsed/Refractory Chronic Lymphocytic Leukemia?

There are 1 clinical trial targeting Relapsed/Refractory Chronic Lymphocytic Leukemia tracked by BioSniper.

What is the prevalence of Relapsed/Refractory Chronic Lymphocytic Leukemia?

The estimated prevalence of Relapsed/Refractory Chronic Lymphocytic Leukemia is approximately 20.0 per 100,000 population.

Deep-dive into Relapsed/Refractory Chronic Lymphocytic Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Relapsed/Refractory Chronic Lymphocytic Leukemia — Drugs in Development & Clinical Trials | BioSniper